Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:31:48 EDT Thu 30 Mar 2023
Enter Symbol
or Name
USA
CA



News for U:XFOR from 2022-03-31 to 2023-03-30 - 28 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-03-21 06:05U:XFORNews ReleaseX4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
2023-03-07 08:01U:XFORNews ReleaseX4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
2023-03-02 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-12 08:30U:XFORNews ReleaseX4 Pharmaceuticals ¢ € ™ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
2022-12-07 08:43U:XFORNews ReleaseX4 Pharmaceuticals Prices $65.0 Million Public Offering
2022-12-06 18:26U:XFORNews ReleaseX4 Pharmaceuticals Announces Proposed Public Offering
2022-11-29 16:01U:XFORNews ReleaseX4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
2022-11-08 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Present at Stifel Healthcare Conference
2022-11-04 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-03 06:05U:XFORNews ReleaseX4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-10-26 08:00U:XFORNews ReleaseX4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
2022-10-20 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
2022-09-27 07:50U:XFORNews ReleaseX4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor's Broad Potential in Chronic Neutropenia (CN)
2022-08-31 08:30U:XFORNews ReleaseX4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia
2022-08-08 16:05U:XFORNews ReleaseX4 Pharmaceuticals to Present at Canaccord Genuity's 42nd Annual Growth Conference
2022-08-04 07:05U:XFORNews ReleaseX4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-07-26 16:05U:XFORNews ReleaseX4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
2022-07-20 16:10U:XFORNews ReleaseX4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones
2022-07-01 16:30U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-30 19:53U:XFORNews ReleaseX4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
2022-06-23 07:00U:XFORNews ReleaseViridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
2022-05-16 06:05U:XFORNews ReleaseX4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor
2022-05-12 06:05U:XFORNews ReleaseX4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-03 06:05U:XFORNews ReleaseX4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022
2022-05-02 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-08 13:05U:XFORNews ReleaseX4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
2022-04-04 08:05U:XFORNews ReleaseX4 Pharmaceuticals to Present at April Investor Conferences
2022-04-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)